Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Vivus Comments On Sam Colin's Claims; Urges Stockholders To Support Board

RELATED NEWS
Trade VVUS now with 

Vivus Inc. (VVUS: Quote), a biopharmaceutical company, announced that it believes First Manhattan Co.'s recent letter to stockholders contains several highly questionable claims and would like to set the record straight. Vivus urged its stockholders not to be misled by Sam Colin and His Hedge Fund, First Manhattan Co.

Vivus's Board recommended that stockholders vote "FOR" all of the company's directors on the GOLD proxy card. They are Leland Wilson, Peter Tam; Mark Logan; Martin Carroll, Charles Casamento, Ernest Mario, Jorge Plutzky, Linda Dairiki Shortliffe, and Robert Wilson.

Responding to a claim by First Manhattan that vivus's CEO Leland Wilson has zero experience in launching blockbuster drugs into the US market, Vivus said that Leland Wilson has extensive experience in new drug commercialization, including Top ranked Sales Director in the U.S. for Naprosyn (Syntex Laboratories, Inc.), which was one of the largest selling drugs in the U.S. at the time.

Vivus also said that Sam Colin's chart showing the price per share of vivus stock from FDA approval of Qsymia to the present is misleading because it fails to show that the stock price saw a three-fold increase in the six months prior to FDA approval. His use of the expense chart demonstrates his lack of understanding that investment is needed for the commercial launch of Qsymia and the work necessary to build the market during the time when the restricted mail-order only REMS distribution was in place.

Sam Colin's various misleading claims ultimately demonstrate a fundamental lack of understanding of the financial, commercial, regulatory and political challenges to launching a drug in multiple jurisdictions in a therapeutic category that did not previously exist, Vivus said.

"The Board and management team call on Sam Colin to refrain from continuing to make false and misleading claims in his "win at all costs" attempt to prevail in a proxy fight that we believe he is waging for personal reasons," Vivus said.

"In Sam Colin's latest letter, he makes multiple references to Warren Buffett. Warren Buffett is one of the country's most well regarded and legendary investors. Sam Colin is certainly NO Warren Buffett," Vivus also said.

Register
To receive FREE breaking news email alerts for VIVUS INC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Policymakers of Reserve Bank of Australia decided to maintain its record low interest rate once again as they continue to assess that the most prudent course is a period of stability in interest rates. The monetary policy board retained the cash rate at 2.50 percent. The rate has been at the current level since August 2013. A ban on athletes using stamina-boosting gases - xenon and argon - came into effect on Monday. The World Anti-Doping Agency (WADA) said Hypoxia-Inducible Factor (HIF) activators Xenon and Argon have been added to the 2014 List of Prohibited Substances and Methods List following the required three-month notice period and UNESCO's communication to all States Parties. A recommendation to revise the British manufacturing growth eased further in August to its lowest level in 14 months as output and demand increased at slower rates, survey results from Markit Economics showed Monday. The Markit/CIPS Purchasing Managers' Index dropped to 52.5 from a revised 54.8 in July. Economists had expected the score to fall to 55.1 from July's original figure of 55.4.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.